Dr. Flowers research spans three areas: 1) epidemiology, outcomes, translational research and clinical trials in lymphoma, 2) oncology informatics projects developing an information infrastructure to support cancer outcomes research, and 3) medical decision analyses and cost-effectiveness analyses aimed at developing strategies to individualize care for cancer patients and improve systems of care. He was involved in the development of national clinical practice guidelines for the management of cancer patients for the American Society of Clinical Oncology, the American College of Radiology, and the American Cancer Society and led the ASCO guideline for the management of febrile neutropenia. Under his leadership the Lymphoma Program at Emory has been a key contributor in clinical trials that have led to new drug approvals by the Food and Drug Administration for four indications cancer patients. In addition, he has led numerous studies investigating the epidemiology, outcomes and health disparities in lymphoma. His current efforts are engaged in constructing the largest prospective cohort study of >12,900 newly diagnosed lymphoma patients with a central biorepository containing stored serum, plasma, extracted constitutional DNA and a tumor bank containing tissue microarrays, tumor DNA and RNA along with clinical, epidemiologic, pathology and treatment data, and longitudinal clinical and patient-reported outcomes. This will serve as an optimal resource for future research in lymphoma epidemiology and outcomes to understand the biological underpinnings of lymphomagenesis and high-risk disease.